IDA

Specialist pharmaceutical company Shield Therapeutics has launched Feraccru (ferric maltol) within the UK to treat adults with iron deficiency anaemia (IDA) in patients affected with inflammatory bowel disease (IBD), who have previously failed on oral iron (ferrous) products.

The two primary forms of IBD include Crohn’s Disease and Ulcerative Colitis, while IDA is the most common non-intestinal symptom of IBD, affecting between 36% to 76% of patients.

Shield Therapeutics founder and chief executive officer Carl Sterritt said: "As part of our ongoing commitment to improve the lives of IDA patients with IBD, we are very pleased to report that they now have access to Feraccru in the UK.

"Based on the highly compelling results generated throughout its clinical trials, we believe that Feraccru is an exciting new oral treatment option for patients who have failed on oral ferrous products. These patients may previously have had to progress to IV iron or might have received no treatment at all.

"As part of our ongoing commitment to improve the lives of IDA patients with IBD, we are very pleased to report that they now have access to Feraccru in the UK."

"We would like to thank all the people who took part in our clinical trials, the investigators and everyone involved in bringing this important product to the market."

The symptoms of IDA, such as fatigue, in IBD patients can significantly affect their daily activities, including their ability to work.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Feraccru (ferric maltol), which is an effective oral ferric iron treatment for IDA, provides a new oral ferric alternative for adult IBD patients with IDA who have failed oral ferrous products.

Feraccru addresses an unmet need in IBD care and also serves as a well-tolerated oral alternative to intravenous (IV) iron in mild to moderate IBD patients.


Image: Micrograph showing inflammation of the large bowel in a case of inflammatory bowel disease. Photo: courtesy of Nephron.